ArticleDrugs & aging2021
Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation.
Article in Drugs & aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Socioeconomic dynamics and tuberculosis mortality in São Paulo: a population-level analysis using spatial modeling.Lancet regional health. Americas · 2026Article
- Global, regional, and national economic value of reducing amenable tuberculosis mortality.Infectious Disease Modelling · 2026Article
- Tuberculosis incidence and mortality trends in mainland China, 2004-2024: control program and elimination progress.Tropical medicine and health · 2026Article
- Tuberculosis notification trends and treatment outcomes in Bangladesh: findings from a National TB Program data, 2019-2021.BMC infectious diseases · 2026Article
- Factors associated with survival of tuberculosis patients in Southeast Iran: comparison of stepwise cox regression, survival tree, and random survival forest.BMC public health · 2025Article
- Clinical characteristics and prognostic factors of pulmonary tuberculosis with interstitial changes.BMC infectious diseases · 2025Article
- Tuberculosis Incidence and Outcomes Among Older New Yorkers.Open forum infectious diseases · 2025Article
- Social participation and exposure to tuberculosis education: a cross-sectional study of older (≥ 60 years) domestic migrants in China.BMC public health · 2025Article
- Age-period-cohort analysis and prediction of tuberculosis trends in China-based on the Global Burden of Disease 2021 data.Frontiers in public health · 2025Article
- Dissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Tumor Budding in Upper Gastrointestinal Carcinomas: A Systematic Review and Meta-Analysis.Cureus · 2024Review
- The Impact of Immune System Aging on Infectious Diseases.Microorganisms · 2024Review
- Treatment patterns and drug survival for generalized pustular psoriasis: A patient journey study using a Japanese claims database.The Journal of dermatology · 2024Article
- Risk Factors for Unfavorable Outcomes of Tuberculosis in Korea: Implications for Patient-Centered Care in Tuberculosis Treatment.Journal of Korean medical science · 2024Article
- Impact of pyrazinamide usage on serious adverse events in elderly tuberculosis patients: A multicenter cohort study.PloS one · 2024Article
- A Study on Risk Factors for Readmission of Elderly Patients with Pulmonary Tuberculosis Within One Month Using Propensity Score Matching Method.Infection and drug resistance · 2024Article
- Article
- Prediction of tuberculosis-specific mortality for older adult patients with pulmonary tuberculosis.Frontiers in public health · 2024Article
- Tuberculosis in older adults: challenges and best practices in the Western Pacific Region.The Lancet regional health. Western Pacific · 2023Review
- Factors associated with adverse drug reactions or death in very elderly hospitalized patients with pulmonary tuberculosis.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proportion of tuberculosis (TB) patients who are older adults is increasing worldwide. Nearly 60% of TB patients in Japan are 70 years or older, and the TB incidence rate in Japan is one of the highest among high-income countries. The previous TB treatment guidelines prior to 2018 in Japan recommended excluding pyrazinamide (PZA) from the initial regimen for patients aged over 80 years.
objectivesWe aimed to examine differences in TB treatment outcomes among different age groups, and between those who received PZA and those who did not.
methodsWe performed a retrospective cohort study of patients with pulmonary TB who were managed at a single medical center in Japan. We compared treatment outcomes and adverse events that resulted in treatment interruption across the age groups.
resultsOf 246 patients, 117 (48%) were aged 75 years or older. Compared with patients aged < 74 years, those ≥ 75 years were less likely to have PZA in the initial regimen (53.0% vs 89.9%; p < 0.0001), more likely to die during treatment (38.5% vs 6.2%; p < 0.0001), and more likely to experience adverse events (30.8% vs 19.4%; p < 0.05). The mortality rate related to TB at 2 months after TB treatment initiation was 28% in those aged ≥ 84 years. Furthermore, among patients aged ≥ 84 years, those who did not receive PZA were significantly more likely to die than those who did (65.8% vs 36.8%; p < 0.05).
conclusionsPatients aged ≥ 75 years with pulmonary TB experienced increased mortality related to TB during treatment and more frequent adverse events than younger patients, even though PZA was often avoided among older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.